Related Experiment Video
Updated: May 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Role of oral teriflunomide in the management of multiple sclerosis
Radu Tanasescu1, Nikos Evangelou, Cris S Constantinescu
1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK ; Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Abstract:
The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing-remitting multiple sclerosis is discussed.
Related Concept Videos
Multiple Sclerosis l: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...